Companies /Healthcare

Stryker Corp

NYSE: SYK Medical Devices
$326.38
â–² $4.26 (+1.32%) today
Markets open · 10:51am ET

Q2 2026 Earnings

Reported Jul 30, 2026, 4:09pm ET · SEC source
$3.69
Beat +5.79%
EPS · est. $3.49
$6.6B
Beat +0.15%
Revenue · est. $6.6B
6 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
0+4%+8%Jul 30Jul 31report 4:09pm ETearnings+0.6%+4.1%
0+4%+8%Jul 30Jul 31earnings+0.6%+4.1%
SYK +4.1%S&P 500 +0.6%
0+4%+8%Jul 30Jul 31report 4:09pm ETearnings+0.4%+4.1%
0+4%+8%Jul 30Jul 31earnings+0.4%+4.1%
SYK +4.1%NASDAQ +0.4%
0+4%+8%Jul 29Aug 7report 4:09pm ETearnings+4.2%+6.6%
0+4%+8%Jul 29Aug 7earnings+4.2%+6.6%
SYK +6.6%S&P 500 +4.2%
0+5%+10%Jul 29Aug 7report 4:09pm ETearnings+5.4%+6.6%
0+5%+10%Jul 29Aug 7earnings+5.4%+6.6%
SYK +6.6%NASDAQ +5.4%
−6.42%
Day of report
+4.76%
Next session
+4.09%
One week

Did SYK Beat Earnings? Q2 2026 Results

Stryker posted a convincing second-quarter 2026 beat, with adjusted EPS of $3.69 clearing the $3.49 consensus by 5.79% and marking the company's fifth consecutive quarter of beating EPS estimates, while revenue of $6.59 billion edged past expectations by 0.15% and grew 9.4% year over year. The primary engine behind the quarter's strength was volume-driven organic growth of 9.0%, with MedSurg and Neurotechnology contributing $3.63 billion, up 9.7%, as Endoscopy surged 11.7% and Medical climbed 13.4%, while Orthopaedics added $2.96 billion on the back of Trauma and Extremities rising 11.9%. Adjusted operating income margin expanded 170 basis points to 27.4%, reflecting disciplined cost execution and operational leverage even as the company absorbed $95 million in structural optimization charges tied to portfolio rationalization. Looking ahead, Stryker narrowed its full-year 2026 outlook to organic sales growth of 8.3% to 9.3% and adjusted EPS of $14.95 to $15.10, with modestly positive pricing and a slightly favorable currency tailwind expected at current rates.

Key Takeaways
  • Organic net sales growth of 9.0% driven by increased unit volume
  • Recovery from cybersecurity incident first reported March 11, 2026
  • Adjusted operating income margin expansion of 170 basis points to 27.4%
  • Strong growth in Medical (13.4%), Endoscopy (11.7%), and Trauma and Extremities (11.9%)
  • Modestly positive pricing impact on sales

“We made significant progress in our recovery from the cyber incident, delivering strong growth in sales, earnings per share and operating cash flow in the second quarter.”

Stryker CEO, on the earnings call

Forward Guidance & Outlook

Stryker narrowed its full year 2026 guidance, now expecting organic net sales growth in the range of 8.3% to 9.3% and adjusted net earnings per diluted share in the range of $14.95 to $15.10. Sales guidance includes a modestly positive pricing impact. Foreign exchange is expected to have a slightly favorable impact on both sales and adjusted EPS should rates hold near current levels.

SYK YoY Financials

Q2 2026 vs Q2 2025 · SEC filings Q2 2025 Q2 2026
$0$2.0B$4.0B$6.0B$6.0B$6.6BRevenue$3.7B$4.5BGross Profit$1.4B$1.7BOperating Income$884.0M$1.3BNet Income
$0$2.0B$4.0B$6.0BRevenueGross ProfitOperating IncomeNet Income

SYK Revenue by Segment

MedSurg and Neurotechnology$3.6B+9.7%
Orthopaedics$3.0B+9.1%
Medical$1.1B+13.4%
Endoscopy$1.0B+11.7%
Trauma and Extremities$1.1B+11.9%
Instruments$1.0B+9.3%
Knees$693.0M+8.4%
Other Orthopaedics$717.0M+10.3%

SYK Revenue by Geography

United States$5.0B+8.9%
Rest of World$1.6B+11.0%

Figures from SEC filings and company reports. Not investment advice.